Cardiovascular

cardiovascular

Educational resources

Image of first page of Guidelines summary card NICE TA607

NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

2019-10-24T10:32:00+01:00Commissioned by Bayer

The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.

Image of Xarelto SMC card (Sep 2019)

Xarelto® ▼ (rivaroxaban) SMC2128

2019-03-14T13:25:00+00:00Commissioned by Bayer

Information intended for healthcare professionals only.

20190820 Renal impairment Algorithm_PI update

Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment

2019-01-10T12:34:00+00:00Commissioned by Bayer

This NOAC dosing guide has been commissioned by Bayer, who also provided funding for its development. Bayer reviewed and approved the scope and pre-meeting documents, suggested the Chair and experts for the group, and put the dosing guide through full medical approval to ensure its compliance with appropriate regulations. The ...

Related Guidelines in Practice articles